A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Not yet recruiting
Sunshine Lake Pharma Co., Ltd.
Phase 3
2023-05-01
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to
Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants
with type 2 diabetes (T2D).
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 2
2008-01-01
This trial is conducted in Africa, Asia and North America. The aim of this trial is to
compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin
glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Completed
Novo Nordisk A/S
Phase 2
2008-01-01
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of
this trial is to compare two NN1250 (insulin degludec) formulations with each other and with
insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.
Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 2
2008-01-01
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble
Insulin Analogue Combination [SIAC], insulin degludec/insulin aspart) formulations with each
other and with biphasic insulin aspart 30, all in combination with metformin in insulin naive
subjects with type 2 diabetes.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
